PharmX Technologies (ASX:PHX) Cash-to-Debt : 42.90 (As of Dec. 2023)

View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PharmX Technologies's cash to debt ratio for the quarter that ended in Dec. 2023 was 42.90.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PharmX Technologies could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for PharmX Technologies's Cash-to-Debt or its related term are showing as below:

ASX:PHX' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.17 Med: No Debt Max: No Debt
Current: 42.9

During the past 13 years, PharmX Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 3.17. And the median was No Debt.

ASX:PHX's Cash-to-Debt is ranked better than
87.44% of 661 companies
in the Healthcare Providers & Services industry
Industry Median: 0.69 vs ASX:PHX: 42.90

PharmX Technologies Cash-to-Debt Historical Data

The historical data trend for PharmX Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PharmX Technologies Cash-to-Debt Chart

PharmX Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

3.17

20.18

17.67

400.19

PharmX Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															17.43	17.67	29.74	400.19	42.90

Competitive Comparison of PharmX Technologies's Cash-to-Debt

For the Health Information Services subindustry, PharmX Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmX Technologies's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's Cash-to-Debt falls into.

PharmX Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PharmX Technologies's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12.806	/	(0.032	+	0)
	=	400.19

PharmX Technologies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12.44	/	(0.102	+	0.188)
	=	42.90

PharmX Technologies (ASX:PHX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PharmX Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmX Technologies (ASX:PHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000

Website

https://www.corumgroup.com.au

PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.